This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
18
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
ICON plc
Millcreek, Utah, United States
Maximum observed plasma concentration (Cmax)
Time frame: Up to 26 days
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])
Time frame: Up to 26 days
Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC[0-T])
Time frame: Up to 26 days
Time of maximum observed serum concentration (Tmax)
Time frame: Up to 26 days
Apparent terminal phase half-life (T-Half)
Time frame: Up to 26 days
Apparent total body clearance (CLT/F)
Time frame: Up to 26 days
Number of participants with adverse events (AEs)
Time frame: Up to 52 days
Number of participants with vital sign abnormalities
Time frame: Up to 28 days
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 21 days
Number of participants with physical examination abnormalities
Time frame: Up to 28 days
Number of participants with clinical laboratory abnormalities
Time frame: Up to 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Intensity of Suicidal Ideation as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) Score
Time frame: Up to 28 days